Patents Assigned to Viron Therapeutics
  • Publication number: 20230414650
    Abstract: The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc at appropriate concentrations to mitigate infections by enveloped viruses, such as COVID-19 virus (SARS-CoV-2), influenza and HIV. While the different forms of cyclodextrin prevent the entry of coated viruses into host cells by extracting and sequestering cholesterol molecules at the virus envelope and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. SUBSTANCE: This formulation is adapted for both surface use and introduction to a subject by dispersal, utilizing the known methods of measured nasal sprays or inhalers, wet wipes and medicated masks. The formulation is introduced in the form of an aqueous phosphate buffered saline pH 7.5 solution, containing 0.
    Type: Application
    Filed: March 19, 2021
    Publication date: December 28, 2023
    Applicant: Viron Therapeutics LLC
    Inventors: Bhanu Pratap Jena, Octavian Bucur
  • Publication number: 20230082992
    Abstract: The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-CoV-2, influenza and HIV/AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.
    Type: Application
    Filed: September 11, 2021
    Publication date: March 16, 2023
    Applicant: Viron Therapeutics LLC
    Inventor: Bhanu Pratap Jena
  • Publication number: 20120270793
    Abstract: Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 25, 2012
    Applicant: Viron Therapeutics Inc.
    Inventor: Alexandra R. Lucas
  • Patent number: 8268331
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 18, 2012
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 8227569
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 24, 2012
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Publication number: 20110064757
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Application
    Filed: May 7, 2009
    Publication date: March 17, 2011
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 7906483
    Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: March 15, 2011
    Assignee: Viron Therapeutics Inc.
    Inventors: Alexandra Lucas, Z. Robert Zhong, D. Grant McFadden
  • Publication number: 20100331524
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 30, 2010
    Applicant: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 7745396
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: June 29, 2010
    Assignee: Viron Therapeutics Inc.
    Inventor: Alexandra Lucas
  • Patent number: 7718368
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: May 18, 2010
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 7585507
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: September 8, 2009
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 7514405
    Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: April 7, 2009
    Assignee: Viron Therapeutics Inc.
    Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden
  • Publication number: 20090011979
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Application
    Filed: August 17, 2006
    Publication date: January 8, 2009
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 7419670
    Abstract: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1/immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: September 2, 2008
    Assignee: Viron Therapeutics, Inc.
    Inventors: Robert Z. Zhong, Alexandra Lucas, Grant D. McFadden
  • Publication number: 20080070841
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Application
    Filed: September 7, 2007
    Publication date: March 20, 2008
    Applicant: Viron Therapeutics, Inc.
    Inventor: Alxandria Lucas
  • Patent number: 7285530
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: October 23, 2007
    Assignee: Viron Therapeutics, Inc.
    Inventor: Alexandra Lucas
  • Publication number: 20060286125
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Application
    Filed: May 9, 2005
    Publication date: December 21, 2006
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 7101559
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immune-related diseases.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: September 5, 2006
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 6894155
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: May 17, 2005
    Assignee: Viron Therapeutics
    Inventors: Grant McFadden, Karim Essani
  • Publication number: 20030171263
    Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
    Type: Application
    Filed: March 13, 2003
    Publication date: September 11, 2003
    Applicant: Viron Therapeutics, Inc.
    Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden